POLIO
MCID: PLM031
MIFTS: 61

Poliomyelitis (POLIO)

Categories: Infectious diseases, Neuronal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Poliomyelitis

MalaCards integrated aliases for Poliomyelitis:

Name: Poliomyelitis 12 77 54 60 45 15 17 74
Infantile Paralysis 54 74
Polio 54 56

Characteristics:

Orphanet epidemiological data:

60
poliomyelitis
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Childhood; Age of death: any age;

Classifications:

Orphanet: 60  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:4953
ICD9CM 36 045 045.9
MeSH 45 D011051
NCIt 51 C35550
SNOMED-CT 69 54839009
ICD10 34 A80 A80.9
MESH via Orphanet 46 D011051
ICD10 via Orphanet 35 A80.0 A80.1 A80.2 more
UMLS via Orphanet 75 C0032371
Orphanet 60 ORPHA2912

Summaries for Poliomyelitis

NIH Rare Diseases : 54 Poliomyelitis is a viral disease that can affect nerves and can lead to partial or full paralysis. It is caused by infection with the poliovirus which can be spread by direct person-to-person contact, by contact with infected mucus or phlegm from the nose or mouth, or by contact with infected feces. There are three basic patterns of polio infection: subclinical infections, nonparalytic, and paralytic. Symptoms vary based on the pattern of infection and can range from asymptomatic with subclinical poliomyelitis to partial or full paralysis. Treatment is aimed at controlling symptoms while the infection runs its course. Since the development of the polio vaccine, the incidence of the disease has been greatly reduced. The prognosis depends on the form of the disease (subclinical, nonparalytic, or paralytic) and the site affected.

MalaCards based summary : Poliomyelitis, also known as infantile paralysis, is related to paralytic poliomyelitis and tetanus. An important gene associated with Poliomyelitis is PVR (PVR Cell Adhesion Molecule), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Phenol and Neomycin have been mentioned in the context of this disorder. Affiliated tissues include testes, spinal cord and bone, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 A viral infectious disease that results in destruction located in motor neurons, has material basis in Human poliovirus 1, has material basis in Human poliovirus 2, or has material basis in Human poliovirus 3, which are transmitted by ingestion of food or water contaminated with feces, or transmitted by direct contact with the oral secretions. The infection has symptom fever, has symptom sore throat, has symptom headache, has symptom vomiting, has symptom fatigue, has symptom neck stiffness, has symptom muscle spasms, and has symptom acute flaccid paralysis.

Wikipedia : 77 Polio, also called poliomyelitis or infantile paralysis, is an infectious disease caused by the... more...

Related Diseases for Poliomyelitis

Diseases related to Poliomyelitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 406)
# Related Disease Score Top Affiliating Genes
1 paralytic poliomyelitis 33.5 ARHGEF1 DPT PVR
2 tetanus 31.0 IFNG IL10 IL4
3 meningitis 30.6 IFNG IL10 TNF
4 rubella 30.6 IL10 IL4 TNF
5 aseptic meningitis 30.5 IFNG IL10 TNF
6 transient hypogammaglobulinemia 30.1 IL10 TNF
7 conjunctivitis 30.1 ICAM1 IFNG IL4
8 human immunodeficiency virus infectious disease 30.1 IFNG IL10 TNF
9 hepatitis a 30.0 IFNG IL10 TNF
10 behcet syndrome 30.0 IFNG IL10 TNF
11 neuritis 29.9 IFNG IL4 TNF
12 acquired immunodeficiency syndrome 29.9 IFNG IL10 TNF
13 sleep apnea 29.9 ICAM1 LEP TNF
14 osteomyelitis 29.8 IFNG IL10 TNF
15 mouth disease 29.8 IFNG IL10 TNF
16 penicillin allergy 29.8 IFNG IL4
17 multiple sclerosis 29.8 ICAM1 IFNG IL10 IL4 TNF
18 leprosy 3 29.8 IFNG IL10 TNF
19 gastroenteritis 29.8 IL10 IL4 TNF
20 reactive arthritis 29.7 IFNG IL10 TNF
21 myasthenia gravis 29.7 IFNG IL10 IL4 TNF
22 erythema multiforme 29.6 ICAM1 IFNG TNF
23 hemophagocytic lymphohistiocytosis 29.5 IFNG IL10 TNF
24 pulmonary edema 29.5 ICAM1 IL10 TNF
25 peritonitis 29.5 ICAM1 IL10 TNF
26 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 29.5 BTK IFNG IL10 IL4
27 asthma 29.4 ICAM1 IFNG IL10 IL4 LEP TNF
28 lichen planus 29.4 ICAM1 IFNG IL4 TNF
29 brucellosis 29.4 IFNG IL10 IL4 TNF
30 chlamydia 29.4 IFNG IL10 IL4 TNF
31 schistosomiasis 29.4 IFNG IL10 IL4 TNF
32 common variable immunodeficiency 28.9 BTK IFNG IL10 IL4 TNF
33 rheumatoid arthritis 28.8 ICAM1 IFNG IL10 IL4 TNF
34 nonparalytic poliomyelitis 12.6
35 poliomyelitis in patients with immunodeficiencies deemed at risk 12.1
36 bulbar polio 12.0
37 postpoliomyelitis syndrome 11.7
38 motor neuron disease 11.4
39 spastic diplegia 11.1
40 spinal cord disease 11.1
41 foot drop 11.1
42 spinal polio 11.1
43 bulbospinal polio 11.1
44 diphtheria 10.7
45 pertussis 10.6
46 measles 10.5
47 nonalcoholic steatohepatitis 10.4 LEP TNF
48 nontuberculous mycobacterial lung disease 10.4 LEP TNF
49 microscopic colitis 10.4 IFNG TNF
50 crohn's colitis 10.4 IFNG TNF

Graphical network of the top 20 diseases related to Poliomyelitis:



Diseases related to Poliomyelitis

Symptoms & Phenotypes for Poliomyelitis

MGI Mouse Phenotypes related to Poliomyelitis:

47 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.18 ARHGEF1 BTK DLG1 FCGR3B ICAM1 IFNG
2 homeostasis/metabolism MP:0005376 10.16 ARHGEF1 BTK DLG1 FCGR3B ICAM1 IFNG
3 growth/size/body region MP:0005378 10.15 BTK DLG1 DPT ICAM1 IFNG IL10
4 digestive/alimentary MP:0005381 10.13 BTK DLG1 ICAM1 IFNG IL10 IL4
5 immune system MP:0005387 10.13 ARHGEF1 BTK DLG1 FCGR3B ICAM1 IFNG
6 endocrine/exocrine gland MP:0005379 10.05 DLG1 ICAM1 IFNG IL10 IL4 LEP
7 integument MP:0010771 10.01 BTK DPT ICAM1 IFNG IL10 IL4
8 muscle MP:0005369 9.91 ARHGEF1 DLG1 ICAM1 IFNG IL10 LEP
9 neoplasm MP:0002006 9.8 BTK ICAM1 IFNG IL10 LEP TNF
10 no phenotypic analysis MP:0003012 9.73 DLG1 FCGR3B IFNG IL10 IL4 TNF
11 respiratory system MP:0005388 9.63 DLG1 IFNG IL10 IL4 LEP TNF
12 skeleton MP:0005390 9.5 DLG1 FCGR3B IFNG IL10 IL4 LEP
13 vision/eye MP:0005391 9.23 DLG1 DPT ICAM1 IFNG IL10 IL4

Drugs & Therapeutics for Poliomyelitis

Drugs for Poliomyelitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 134)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Phenol Approved, Experimental Phase 4 108-95-2 996
2
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
3
Polymyxin B Approved, Vet_approved Phase 4 1404-26-8
4
Zinc sulfate Approved, Investigational Phase 4,Not Applicable 7733-02-0
5
Calcium Carbonate Approved, Investigational Phase 4 471-34-1
6
Zinc Approved, Investigational Phase 4,Not Applicable 7440-66-6 32051
7
Pentetic acid Approved Phase 4,Phase 3,Phase 2 67-43-6
8
Iron Approved, Experimental Phase 4,Phase 3,Phase 2 7439-89-6, 15438-31-0 23925 27284
9
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 62-33-9, 60-00-4 6049
10
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
11
Ibuprofen Approved Phase 4,Phase 2 15687-27-1 3672
12
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
13
Inulin Approved, Investigational, Nutraceutical Phase 4 9005-80-5 24763
14
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2 7440-70-2 271
15
BCG vaccine Investigational Phase 4,Phase 2,Not Applicable
16 Antibodies, Blocking Phase 4
17 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
18 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Antibodies Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
20 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Adjuvants, Immunologic Phase 4,Phase 1,Phase 2,Not Applicable
22 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
23 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
24 Nutrients Phase 4,Phase 2,Phase 3,Not Applicable
25 Trace Elements Phase 4,Phase 2,Phase 3,Not Applicable
26 Micronutrients Phase 4,Phase 2,Phase 3,Not Applicable
27 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 1,Phase 2
28 Retinol palmitate Phase 4,Phase 2,Phase 3,Not Applicable
29 Antioxidants Phase 4,Phase 2,Phase 3,Not Applicable
30 Vitamins Phase 4,Phase 2,Phase 3,Not Applicable
31 retinol Phase 4,Phase 2,Phase 3,Not Applicable
32 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
33 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Polymyxins Phase 4
35 Calcium, Dietary Phase 4,Phase 3,Phase 2
36 Acidophilus Phase 4
37 Zinc Supplement Phase 4,Not Applicable
38 Anticoagulants Phase 4,Phase 3,Phase 2
39 PENTA Phase 4,Phase 3,Phase 2,Not Applicable
40 Fibrinolytic Agents Phase 4,Phase 3,Phase 2
41 Chelating Agents Phase 4,Phase 3,Phase 2
42 Iron Chelating Agents Phase 4,Phase 3,Phase 2
43 Antidotes Phase 4,Phase 3,Phase 2
44 Anti-Inflammatory Agents Phase 4,Phase 2
45 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
46 Cyclooxygenase Inhibitors Phase 4,Phase 2
47 Antipyretics Phase 4,Phase 3
48 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
49 Analgesics Phase 4,Phase 3,Phase 2
50 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 373)
# Name Status NCT ID Phase Drugs
1 Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV Vaccine Unknown status NCT01841671 Phase 4
2 Diphtheria, Tetanus, Poliomyelitis -Pertussis-Hib Immunisation in Preterm-born Neonates Unknown status NCT02179996 Phase 4
3 Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand Unknown status NCT02408926 Phase 4
4 Influence of BCG on TDaP-IPV Vaccination Unknown status NCT02771782 Phase 4
5 Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan Completed NCT02005536 Phase 4
6 A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China Completed NCT01278433 Phase 4
7 Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine Completed NCT01475539 Phase 4
8 A Study of the Safety of IMOVAX Polio™ in China Completed NCT01244464 Phase 4
9 A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of Age Completed NCT02580201 Phase 4
10 Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults Completed NCT01323959 Phase 4
11 Polio End-game Strategies - Poliovirus Type 2 Challenge Study Completed NCT02189811 Phase 4
12 Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine Completed NCT00514059 Phase 4 Boostrix polio
13 Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE Completed NCT01546909 Phase 4
14 A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania Completed NCT02582255 Phase 4
15 A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children Completed NCT02521974 Phase 4
16 Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines Completed NCT01616693 Phase 4
17 Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine Completed NCT01831050 Phase 4
18 Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine Completed NCT00635128 Phase 4
19 Regulatory Post-Marketing Surveillance Study for TETRAXIM™ Completed NCT01437423 Phase 4
20 Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules Completed NCT02412514 Phase 4
21 Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine Completed NCT02643368 Phase 4
22 Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia Completed NCT01094171 Phase 4
23 IPV in Moderate to Severe Chronic Malnourished 9-12 Month Old Children in Karachi. Completed NCT01695798 Phase 4
24 IPV Clinical Trial - The Gambia Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
25 Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study Completed NCT02847026 Phase 4
26 Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants Completed NCT03147560 Phase 4
27 Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Completed NCT00254917 Phase 4
28 Inactivated Influenza Vaccine Effectiveness in Tropical Africa Completed NCT00893906 Phase 4
29 Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine Completed NCT00304265 Phase 4
30 Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02422264 Phase 4 Prevnar13
31 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
32 Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age Completed NCT01031303 Phase 4
33 Immunogenicity and Safety Profile of Primary Dose of bOPV Bio Farma Given Simultaneously With Pentabio And IPV Completed NCT03310073 Phase 4
34 Direct and Indirect Protection by Influenza Vaccine Given to Children in India Completed NCT00934245 Phase 4
35 Non-Specific Effects of Standard Titre Measles Vaccination Completed NCT00168662 Phase 4
36 Poliovirus Vaccine Trial in Bangladesh Completed NCT01633216 Phase 4
37 Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants Completed NCT02907216 Phase 4
38 Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants Completed NCT00325156 Phase 4
39 Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children Completed NCT00611559 Phase 4
40 Different Doses of Vitamin A and Childhood Morbidity and Mortality Completed NCT00168584 Phase 4 Vitamin A
41 Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course Completed NCT01457547 Phase 4
42 Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ Completed NCT01358825 Phase 4
43 Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China Completed NCT01491087 Phase 4
44 Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Completed NCT00753649 Phase 4
45 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Completed NCT01659996 Phase 4
46 Hepatitis B Vaccination in Infants Completed NCT01896596 Phase 4
47 A Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants Completed NCT02145624 Phase 4 Repevax;Boostrix-IPV
48 Trial of Two Strains of BCG Completed NCT02447536 Phase 4
49 Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13® Completed NCT01392378 Phase 4 Paracetamol;Ibuprofen;Paracetamol;Ibuprofen
50 Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060) Completed NCT01926015 Phase 4

Search NIH Clinical Center for Poliomyelitis

Cochrane evidence based reviews: poliomyelitis

Genetic Tests for Poliomyelitis

Anatomical Context for Poliomyelitis

MalaCards organs/tissues related to Poliomyelitis:

42
Testes, Spinal Cord, Bone, Lung, Brain, Breast, Liver

Publications for Poliomyelitis

Articles related to Poliomyelitis:

(show top 50) (show all 3370)
# Title Authors Year
1
Acute flaccid myelitis in the 21st century: reminiscence of poliomyelitis or a new emergent disease. ( 30885376 )
2019
2
Evaluation of the genetic stability of Sabin strains and the consistency of inactivated poliomyelitis vaccine made from Sabin strains using direct deep-sequencing. ( 30467062 )
2019
3
First case in China of vaccine-associated poliomyelitis after sequential Inactivated and bivalent oral polio vaccination. ( 30630693 )
2019
4
Outcome of femoral fractures in poliomyelitis patients. ( 30643935 )
2019
5
Neurological Symptoms in Danes with a History of Poliomyelitis: Lifelong Follow-Up of Late Symptoms, their Association with Initial Symptoms of Polio, and Presence of Postpolio Syndrome. ( 30836354 )
2019
6
Post-Polio Syndrome and the Late Effects of Poliomyelitis: Part 2. Treatment, Management and Prognosis. ( 29752826 )
2018
7
Total Hip Arthroplasty for Patients with Residual Poliomyelitis at a Mean Eight Years of Follow-up. ( 29674772 )
2018
8
Total hip arthroplasty in patients affected by poliomyelitis. ( 29855245 )
2018
9
Total Hip Arthroplasty for Patients with Residual Poliomyelitis at a Mean Eight Years of Follow-up. ( 29463934 )
2018
10
Technical aspects and complications in the surgical treatment of poliomyelitis-affected lower limb fractures. ( 29605559 )
2018
11
Post-Polio Syndrome and the Late Effects of Poliomyelitis: Part 1. Pathogenesis, Biomechanical Considerations, Diagnosis, and Investigations. ( 29752819 )
2018
12
Vaccine-associated paralytic poliomyelitis in a patient with acute lymphocytic leukemia. ( 29322435 )
2018
13
Good practices and challenges in addressing poliomyelitis and measles in the European Union. ( 29659793 )
2018
14
Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis. ( 29925653 )
2018
15
A Two-Stage Foot Repair in a 55-Year-Old Man with Poliomyelitis. ( 29547029 )
2018
16
Preparedness and response against diseases with epidemic potential in the European Union: a qualitative case study of Middle East Respiratory Syndrome (MERS) and poliomyelitis in five member states. ( 29976185 )
2018
17
Progress Toward Poliomyelitis Eradication - Nigeria, January-December 2017. ( 29494568 )
2018
18
Recipient vaccine-associated paralytic poliomyelitis in China, 2010-2015. ( 29395524 )
2018
19
Progress towards poliomyelitis eradication: Nigeria, Januarya89December 2017. ( 29498497 )
2018
20
On reducing the risk of vaccine-associated paralytic poliomyelitis in the global transition from oral to inactivated poliovirus vaccine. ( 29605427 )
2018
21
Vaccine-associated paralytic poliomyelitis in the Russian Federation in 1998-2014. ( 30201507 )
2018
22
Pediatric HIV Infection and Decreased Prevalence of OPV Point Mutations Linked to Vaccine-associated Paralytic Poliomyelitis. ( 30376083 )
2018
23
Outcome of total knee arthroplasty in patients with poliomyelitis: A systematic review. ( 30034816 )
2018
24
Progress Toward Poliomyelitis Eradication - Afghanistan, January 2017-May 2018. ( 30070983 )
2018
25
Childhood Limb Poliomyelitis as a Suspected Etiology for a Contra-Lateral Femoral Arteriomegaly and Aneurysm Formation. ( 30109799 )
2018
26
Estimation of the Direct Cost of Poliomyelitis Rehabilitation Treatment to Pakistani Patients: A 53-Year Retrospective Study. ( 30128833 )
2018
27
Poliomyelitis era in Trinidad from 1940 to 1972 and beyond: Implications for effective global health governance for its eradication. ( 30234035 )
2018
28
Seroprevalence of Poliomyelitis Antibodies Among Children Aged 1 to 4 Years Old and Factors Associated With Poliovirus Susceptibility; Mexican Health and Nutrition Survey, 2012. ( 30376082 )
2018
29
Progress Toward Poliomyelitis Eradication - Pakistan, January 2017-September 2018. ( 30408024 )
2018
30
For how long do denervated muscles in children retain the ability to regenerate?: Restoration of elbow flexion and shoulder function by partial nerve transfer in a child with long-standing poliomyelitis-like paralysis. ( 30424927 )
2018
31
Radiographic and Clinical Outcomes of Surgical Correction of Poliomyelitis-Related Spinal Deformities: A Comparison Among Three Types of Pelvic Instrumentations. ( 30439526 )
2018
32
The Contribution of Poliomyelitis to President Roosevelt's Heart Failure. A Lesson on the Importance of Vaccinations for Cardiovascular Prevention. ( 30456727 )
2018
33
An ethical appraisal of the choice of vaccines against Poliomyelitis. ( 30473498 )
2018
34
Poliomyelitis. ( 30482325 )
2018
35
Distal Femoral Flexion Closing Wedge Osteotomy for Treatment of Failed Chronic Distal Femoral Extension Osteotomy in a Patient With Poliomyelitis. ( 30777837 )
2018
36
Poliomyelitis eradication a89 the review of notifications from the years 2010-2016 sent to National IHR Focal Point ( 28654739 )
2017
37
Progress towards poliomyelitis eradication: Afghanistan, January 2016a89June 2017. ( 28819963 )
2017
38
The push to eradicate poliomyelitis in the Eastern Mediterranean Region. ( 29178113 )
2017
39
A case-control study on the association of pulse oral poliomyelitis vaccination and Gianotti-Crosti syndrome. ( 27943306 )
2017
40
Introduction of Inactivated Poliovirus Vaccine and Impact on Vaccine-Associated Paralytic Poliomyelitis - Beijing, China, 2014-2016. ( 29240729 )
2017
41
Progress Toward Poliomyelitis Eradication - Pakistan, January 2016-September 2017. ( 29166363 )
2017
42
Vaccine Associated Paralytic Poliomyelitis Unmasking Common Variable Immunodeficiency. ( 28361789 )
2017
43
Negative or positive? The iron lung and poliomyelitis-Zurich, 1951. ( 28675796 )
2017
44
Knowledge assessment regarding poliomyelitis among the caregivers of children who received oral polio vaccine reveals lack of awareness of the vaccine vial monitor (VVM): Implications extending beyond polio eradication. ( 28121284 )
2017
45
Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial. ( 28362135 )
2017
46
Risk factors and short-term projections for serotype-1 poliomyelitis incidence in Pakistan: A spatiotemporal analysis. ( 28604777 )
2017
47
Understanding the Dynamics of Poliomyelitis Spread in Pakistan. ( 28845415 )
2017
48
'A matter of commonsense': the Coventry poliomyelitis epidemic 1957 and the British public. ( 29118656 )
2017
49
Budget impact of polio immunization strategy for India: introduction of one dose of inactivated poliomyelitis vaccine and reductions in supplemental polio immunization. ( 28057194 )
2017
50
A systematic review of the worldwide prevalence of survivors of poliomyelitis reported in 31 studies. ( 28694346 )
2017

Variations for Poliomyelitis

Expression for Poliomyelitis

Search GEO for disease gene expression data for Poliomyelitis.

Pathways for Poliomyelitis

Pathways related to Poliomyelitis according to GeneCards Suite gene sharing:

(show all 46)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 BTK FCGR3A FCGR3B ICAM1 IFNG IL10
2
Show member pathways
13.42 ARHGEF1 BTK ICAM1 IFNG IL10 IL4
3
Show member pathways
12.78 ICAM1 IFNG IL10 IL4 TNF
4
Show member pathways
12.55 BTK IFNG IL10 IL4 TNF
5
Show member pathways
12.51 IFNG IL10 IL4 TNF
6
Show member pathways
12.48 ICAM1 IFNG IL4 TNF
7 12.45 BTK IFNG IL10 IL4 PVR TNF
8
Show member pathways
12.39 FCGR3A FCGR3B ICAM1 IFNG IL4 TNF
9
Show member pathways
12.35 DLG1 IFNG IL10 IL4 TNF
10
Show member pathways
12.32 IFNG IL10 IL4 LEP
11
Show member pathways
12.25 ICAM1 IFNG IL4 TNF
12
Show member pathways
12.18 IFNG IL10 IL4 TNF
13 12.17 FCGR3A FCGR3B IFNG IL10 TNF
14
Show member pathways
12.09 IFNG IL4 TNF
15 12.01 ICAM1 IFNG TNF
16
Show member pathways
12 BTK ICAM1 IFNG IL10 IL4
17 11.99 FCGR3A ICAM1 PVR
18
Show member pathways
11.97 IFNG IL10 TNF
19 11.93 IFNG IL10 IL4 TNF
20 11.92 ICAM1 IL10 IL4 TNF
21 11.91 BTK FCGR3A FCGR3B IFNG TNF
22
Show member pathways
11.87 FCGR3A FCGR3B IFNG IL4 TNF
23 11.82 IFNG IL10 TNF
24 11.82 BTK ICAM1 TNF
25 11.8 ICAM1 IFNG IL4 LEP TNF
26 11.79 ICAM1 IFNG TNF
27 11.74 ICAM1 IFNG IL4
28 11.74 IFNG IL10 IL4 TNF
29
Show member pathways
11.7 FCGR3A FCGR3B IFNG IL10 IL4 TNF
30
Show member pathways
11.69 IFNG IL4 TNF
31 11.68 IFNG IL10 TNF
32 11.64 FCGR3A FCGR3B ICAM1 IL10
33
Show member pathways
11.6 ICAM1 IFNG TNF
34 11.49 ICAM1 IL10 IL4 TNF
35 11.47 ICAM1 IFNG IL10 TNF
36 11.44 IFNG IL10 IL4
37 11.27 IFNG IL4 TNF
38 11.17 IFNG IL10 IL4
39 11.14 BTK IL10 IL4 TNF
40 11.13 ICAM1 IFNG IL10 TNF
41 11.09 ICAM1 IFNG
42 11.03 LEP TNF
43 10.95 FCGR3A FCGR3B IFNG IL10 IL4 TNF
44 10.93 ARHGEF1 BTK IL10 IL4 TNF
45 10.92 IFNG IL10 IL4 TNF
46 10.88 ICAM1 TNF

GO Terms for Poliomyelitis

Cellular components related to Poliomyelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.76 DPT FCGR3B IFNG IL10 IL4 LEP
2 membrane raft GO:0045121 9.26 BTK DLG1 ICAM1 TNF
3 extracellular space GO:0005615 9.23 DPT ICAM1 IFNG IL10 IL4 LEP

Biological processes related to Poliomyelitis according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.9 ICAM1 IL10 IL4 TNF
2 regulation of signaling receptor activity GO:0010469 9.88 IFNG IL10 IL4 LEP TNF
3 cellular response to lipopolysaccharide GO:0071222 9.83 ICAM1 IL10 TNF
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.82 BTK ICAM1 TNF
5 regulation of immune response GO:0050776 9.81 FCGR3A ICAM1 IL4 PVR
6 response to organic substance GO:0010033 9.78 BTK IL10 TNF
7 response to insulin GO:0032868 9.75 ICAM1 IL10 LEP
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.74 IFNG IL4 LEP
9 regulation of insulin secretion GO:0050796 9.72 IFNG LEP TNF
10 positive regulation of protein localization to plasma membrane GO:1903078 9.67 DLG1 IFNG TNF
11 cortical actin cytoskeleton organization GO:0030866 9.65 DLG1 TNF
12 positive regulation of protein complex assembly GO:0031334 9.65 IFNG TNF
13 positive regulation of osteoclast differentiation GO:0045672 9.64 IFNG TNF
14 leukocyte tethering or rolling GO:0050901 9.64 LEP TNF
15 negative regulation of B cell proliferation GO:0030889 9.63 BTK IL10
16 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.63 IFNG TNF
17 negative regulation of glucose import GO:0046325 9.62 LEP TNF
18 negative regulation of growth of symbiont in host GO:0044130 9.62 IL10 TNF
19 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.61 IL10 TNF
20 negative regulation of lipid storage GO:0010888 9.59 LEP TNF
21 endothelial cell apoptotic process GO:0072577 9.58 IL10 TNF
22 positive regulation of nitric oxide biosynthetic process GO:0045429 9.58 ICAM1 IFNG TNF
23 positive regulation of MHC class II biosynthetic process GO:0045348 9.56 IL10 IL4
24 negative regulation of cytokine secretion involved in immune response GO:0002740 9.54 IL10 TNF
25 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.52 ICAM1 TNF
26 regulation of isotype switching GO:0045191 9.46 IL10 IL4
27 type 2 immune response GO:0042092 9.43 IL10 IL4
28 negative regulation of endothelial cell apoptotic process GO:2000352 9.43 ICAM1 IL10 IL4
29 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.37 IFNG TNF
30 negative regulation of mitotic cell cycle GO:0045930 9.33 DLG1 IL10 TNF
31 receptor biosynthetic process GO:0032800 9.32 IL10 TNF
32 immune response GO:0006955 9.1 FCGR3A FCGR3B IFNG IL10 IL4 TNF
33 positive regulation of vitamin D biosynthetic process GO:0060557 8.96 IFNG TNF

Molecular functions related to Poliomyelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 IgG binding GO:0019864 8.96 FCGR3A FCGR3B
2 cytokine activity GO:0005125 8.92 IFNG IL10 IL4 TNF

Sources for Poliomyelitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....